Treatment Information

Back

Melanoma treatment details. Biologic therapy.

Peking University Cancer Hospital, Beijing, China.

Survival: monthsCountry:China
Toxiciy Grade:4City/State/Province:Beijing
Treatments:Biologic therapyHospital:Peking University Cancer Hospital
Drugs:Journal:Link
Date:Jun 2011

Description:

Patients:
This study involved 43 patients with metastatic melanoma. Patients had a median age of 57 years and 46.5% were male.

Treatment:
Patients were treated with the biologic therapy called imatinib mesylate, which is a tyrosine kinase inhibitor.

Toxicities:
The maximum toxicity reported was grade 4, including 1 case each of neutropenia and psychiatric symptoms and 2 cases of increased liver enzymes (AST/ALT). Grade 3 fatigue, anorexia, nausea, vomiting, and rash were also reported.

Results:
The median progression-free survival and median overall survival was 3.5 and 14.0 months, respectively.

Support:
This study was partially supported by Novartis Oncology in China.

Correspondence: Dr. Jun Guo; email: [email protected]



Back